Showing 1,621 - 1,640 results of 3,189 for search '"vaccine"', query time: 0.07s Refine Results
  1. 1621
  2. 1622
  3. 1623
  4. 1624
  5. 1625

    The safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) in combination with rabies vaccination in Chinese healthy adults: A phase Ib randomized, double-blind, parallel-controlled clinical study by Yin Yin, Min Jia, Yufeng Li, Wei Zhao, Shuhong Chen, Peiyuan Huo, Qinghua Zhao, Lan Yu, Cha Wang, Yirui Ma, Meixia Wang, Jing Zhang

    Published 2025-01-01
    “…This study compared the safety, pharmacokinetics and neutralizing activity of recombinant human anti-rabies monoclonal antibody NM57 injection (rhRIG, Ormutivimab) and HRIG in combination with rabies vaccine and vaccine alone. Method: This randomized, double-blind, parallel-controlled Phase Ib clinical study was conducted in healthy Chinese population to evaluate the safety, pharmacokinetics, and neutralizing activity of rhRIG at dosages of 20IU/kg and 40IU/kg in combination with vaccines, and to compare the neutralizing activity of rhRIG + vaccine with that of HRIG + vaccine and vaccine alone. 72 healthy participants divided into 6 groups of 12 individuals. …”
    Get full text
    Article
  6. 1626

    Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers – the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study protocol by Nick Andrews, Mary Ramsay, Maria Zambon, Victoria Hall, Sarah Wallace, Susan Hopkins, Jean Timeyin, Tim J G Brooks, Amoolya Vusirikala, Meera Chand, Andre Charlett, Sakib Rokadiya, Colin S Brown, Madhumita Shrotri, Peter D Kirwan, Michele Cole, Natalie Gillson, Ana Atti, Sarah Foulkes, Andrew Taylor-Kerr, Blanche Oguti, Jasmin Islam

    Published 2022-06-01
    “…Individuals complete enrolment and fortnightly questionnaires on exposures, symptoms and vaccination. Follow-up is 12 months from study entry, with an option to extend follow-up to 24 months.The primary outcome of interest is infection with SARS-CoV-2 after previous SARS-CoV-2 infection or COVID-19 vaccination during the study period. …”
    Get full text
    Article
  7. 1627
  8. 1628
  9. 1629
  10. 1630
  11. 1631
  12. 1632
  13. 1633

    The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections by Keneth Iceland, Kasozi

    Published 2021
    Subjects: “…COVID-19 therapy; COVID-19 vaccine; COVID-19 convalescent therapy; SARS-CoV-2 infection; human antibodies; variants of concern; Ebola…”
    Get full text
    Article
  14. 1634
  15. 1635
  16. 1636
  17. 1637
  18. 1638
  19. 1639
  20. 1640